分子生物学
IVD分子诊断
细胞培养与分析
蛋白研究
细胞因子
重组蛋白
抗体
高通量测序建库
病原检测UCF系列
生物医药
工具酶
抑制剂激活剂与常用试剂
仪器
耗材

MYSM1 induces apoptosis and sensitizes TNBC cells to cisplatin via RSK3–phospho-BAD pathway

Guan Xiaolin, Meng Xin, Zhu Keyu, Kai Jinyan, Liu Yixuan, Ma Qian, Tong Ying, Zheng Hui, Xie Suhong, Ma Xiaolu, Wang Yanchun, Lu Renquan, Guo Lin

Journal:Cell Death Discovery

IF:7.11

DOI:10.1038/s41420-022-00881-1

PMID:35217648

Published:2022-02-26

research field:肿瘤学分子生物学癌症治疗放射生物学

Abstract

Breast cancer is one of the leading causes of mortality among women. Triple-negative breast cancer (TNBC) is responsible for a large percentage of all breast cancer deaths in women. This study demonstrated the function of Myb-like, SWIRM, and MPN domains 1 (MYSM1), an H2A deubiquitinase (DUB), in TNBC. MYSM1 expression was drastically decreased in breast cancer, especially in TNBC, suggesting a potential anticancer effect. Overexpressing and suppressing MYSM1 expression in TNBC cell lines led to significant biological changes in cell proliferation. Furthermore, MYSM1 overexpression increased cisplatin-induced apoptosis, which might be attributed to RSK3 inactivation and the subsequently decreased phosphorylation of Bcl-2 antagonist of cell death (BAD) (Ser 112). The findings suggest that MYSM1 is a potential target for regulating cell apoptosis and suppressing resistance to cisplatin in TNBC.

本文使用的Yeasen产品

购物车
客服
转染试用